Emerging therapeutics for advanced thyroid malignancies: Rationale and targeted approaches

Pamela Jo Harris, Keith C. Bible

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Introduction: Thyroid cancer is an emerging public health concern. In the USA, its incidence has doubled in the past decade, making it the eighth most commonly diagnosed neoplasm in 2010. Despite this alarming increase, most thyroid cancer patients benefit from conventional approaches (surgery, radioiodine, radiotherapy, TSH suppression with levothyroxine) and are often cured. Nevertheless, a minority have aggressive tumors resistant to cytotoxic and other historical therapies; these patients sorely need new treatment options. Areas covered: Herein the biology and molecular characteristics of the common histological types of thyroid cancer are reviewed to provide context for subsequent discussion of recent developments and emerging therapeutics for advanced thyroid cancers. Expert opinion: Several kinase inhibitors, especially those targeting VEGFR and/or RET, have already demonstrated promising activity in differentiated and medullary thyroid cancers (DTC, MTC). Although of minimal benefit in DTC and MTC, cytotoxic chemotherapy with anti-microtubule agents and/or anthracyclines in combination with intensity-modulated radiation therapy appears to extend survival for patients with locoregionally confined anaplastic thyroid cancer (ATC), but to have only modest benefit in metastatic ATC. Further discovery and development of novel agents and combinations of agents will be critical to further progress in treating advanced thyroid cancers of all histotypes.

Original languageEnglish (US)
Pages (from-to)1357-1375
Number of pages19
JournalExpert Opinion on Investigational Drugs
Volume20
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

Thyroid Neoplasms
Thyroid Gland
Neoplasms
Radiotherapy
Therapeutics
Anthracyclines
Expert Testimony
Thyroxine
Microtubules
Molecular Biology
Phosphotransferases
Public Health
Drug Therapy
Survival
Incidence
Anaplastic Thyroid Carcinoma

Keywords

  • Anaplastic thyroid cancer
  • Differentiated thyroid cancer
  • Medullary thyroid cancer
  • Taxanes
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging therapeutics for advanced thyroid malignancies : Rationale and targeted approaches. / Harris, Pamela Jo; Bible, Keith C.

In: Expert Opinion on Investigational Drugs, Vol. 20, No. 10, 10.2011, p. 1357-1375.

Research output: Contribution to journalArticle

@article{e23f4de262b044dfa66ba208a9910ac8,
title = "Emerging therapeutics for advanced thyroid malignancies: Rationale and targeted approaches",
abstract = "Introduction: Thyroid cancer is an emerging public health concern. In the USA, its incidence has doubled in the past decade, making it the eighth most commonly diagnosed neoplasm in 2010. Despite this alarming increase, most thyroid cancer patients benefit from conventional approaches (surgery, radioiodine, radiotherapy, TSH suppression with levothyroxine) and are often cured. Nevertheless, a minority have aggressive tumors resistant to cytotoxic and other historical therapies; these patients sorely need new treatment options. Areas covered: Herein the biology and molecular characteristics of the common histological types of thyroid cancer are reviewed to provide context for subsequent discussion of recent developments and emerging therapeutics for advanced thyroid cancers. Expert opinion: Several kinase inhibitors, especially those targeting VEGFR and/or RET, have already demonstrated promising activity in differentiated and medullary thyroid cancers (DTC, MTC). Although of minimal benefit in DTC and MTC, cytotoxic chemotherapy with anti-microtubule agents and/or anthracyclines in combination with intensity-modulated radiation therapy appears to extend survival for patients with locoregionally confined anaplastic thyroid cancer (ATC), but to have only modest benefit in metastatic ATC. Further discovery and development of novel agents and combinations of agents will be critical to further progress in treating advanced thyroid cancers of all histotypes.",
keywords = "Anaplastic thyroid cancer, Differentiated thyroid cancer, Medullary thyroid cancer, Taxanes, Tyrosine kinase inhibitors",
author = "Harris, {Pamela Jo} and Bible, {Keith C.}",
year = "2011",
month = "10",
doi = "10.1517/13543784.2011.614230",
language = "English (US)",
volume = "20",
pages = "1357--1375",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Emerging therapeutics for advanced thyroid malignancies

T2 - Rationale and targeted approaches

AU - Harris, Pamela Jo

AU - Bible, Keith C.

PY - 2011/10

Y1 - 2011/10

N2 - Introduction: Thyroid cancer is an emerging public health concern. In the USA, its incidence has doubled in the past decade, making it the eighth most commonly diagnosed neoplasm in 2010. Despite this alarming increase, most thyroid cancer patients benefit from conventional approaches (surgery, radioiodine, radiotherapy, TSH suppression with levothyroxine) and are often cured. Nevertheless, a minority have aggressive tumors resistant to cytotoxic and other historical therapies; these patients sorely need new treatment options. Areas covered: Herein the biology and molecular characteristics of the common histological types of thyroid cancer are reviewed to provide context for subsequent discussion of recent developments and emerging therapeutics for advanced thyroid cancers. Expert opinion: Several kinase inhibitors, especially those targeting VEGFR and/or RET, have already demonstrated promising activity in differentiated and medullary thyroid cancers (DTC, MTC). Although of minimal benefit in DTC and MTC, cytotoxic chemotherapy with anti-microtubule agents and/or anthracyclines in combination with intensity-modulated radiation therapy appears to extend survival for patients with locoregionally confined anaplastic thyroid cancer (ATC), but to have only modest benefit in metastatic ATC. Further discovery and development of novel agents and combinations of agents will be critical to further progress in treating advanced thyroid cancers of all histotypes.

AB - Introduction: Thyroid cancer is an emerging public health concern. In the USA, its incidence has doubled in the past decade, making it the eighth most commonly diagnosed neoplasm in 2010. Despite this alarming increase, most thyroid cancer patients benefit from conventional approaches (surgery, radioiodine, radiotherapy, TSH suppression with levothyroxine) and are often cured. Nevertheless, a minority have aggressive tumors resistant to cytotoxic and other historical therapies; these patients sorely need new treatment options. Areas covered: Herein the biology and molecular characteristics of the common histological types of thyroid cancer are reviewed to provide context for subsequent discussion of recent developments and emerging therapeutics for advanced thyroid cancers. Expert opinion: Several kinase inhibitors, especially those targeting VEGFR and/or RET, have already demonstrated promising activity in differentiated and medullary thyroid cancers (DTC, MTC). Although of minimal benefit in DTC and MTC, cytotoxic chemotherapy with anti-microtubule agents and/or anthracyclines in combination with intensity-modulated radiation therapy appears to extend survival for patients with locoregionally confined anaplastic thyroid cancer (ATC), but to have only modest benefit in metastatic ATC. Further discovery and development of novel agents and combinations of agents will be critical to further progress in treating advanced thyroid cancers of all histotypes.

KW - Anaplastic thyroid cancer

KW - Differentiated thyroid cancer

KW - Medullary thyroid cancer

KW - Taxanes

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=80052784382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052784382&partnerID=8YFLogxK

U2 - 10.1517/13543784.2011.614230

DO - 10.1517/13543784.2011.614230

M3 - Article

C2 - 21910667

AN - SCOPUS:80052784382

VL - 20

SP - 1357

EP - 1375

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 10

ER -